IL Therapeutics
From Wikipedia, the free encyclopedia
| Industry | Biotechnology |
|---|---|
| Headquarters | 105E ñ 111 Research Drive, Saskatoon, SK, Canada |
IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP ("Western Life Sciences") and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation ("Pacgen").[1][2]
Saskatchewan Research Council operates a bioprocessing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine.
Pharmaceuticals
Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P ("PAC-G31P") for relief of Acute Respiratory Distress Syndrome (ARDS).[1] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] With the successful progression of G31P, the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment.[4] This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[5]